Protein Summary
In cancer context, protects cells from induced-DNA damage and apoptosis. Acts, at least in part, through PI3K/AKT/NFKB signaling pathway and by preventing POLB degradation. Decreases POLB ubiquitation and stabilizes its protein levels.
- ENST00000064778
- ENSP00000064778
- ENSG00000054965
- ENST00000356467
- ENSP00000348852
- ENST00000450446
- ENSP00000390501
- KIAA0280
- TCRP1
- TCRP1
- KIAA0280
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
transcription factor binding site profile | 0.91 | ||
kinase perturbation | 0.88 | ||
histone modification site profile | 0.85 | ||
virus perturbation | 0.68 | ||
tissue sample | 0.65 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 16.54 (req: < 5)
Gene RIFs: 8 (req: <= 3)
Antibodies: 39 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 16.54 (req: >= 5)
Gene RIFs: 8 (req: > 3)
Antibodies: 39 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Term: 1
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0